Credit Suisse analyst Judah Frommer reiterated an Outperform rating and $28.00 price target on Esperion Therapeutics (NASDAQ: ESPR) after attending ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE